Immune response of mice to Echinococcus multilocularis infection after therapy with amphotericin B colloidal dispersion

[1] Abbas, A. K., Murphy, K. M., Sher, A. (1996): Functional diversity of helper T lymphocytes. Nature, 383: 787–793 http://dx.doi.org/10.1038/383787a010.1038/383787a0Search in Google Scholar

[2] Abu-Salah, K. M. (1996): Amphotericin B: an update. Brit. J. Biomed. Sci., 53: 122–133 Search in Google Scholar

[3] Ammann, R. W., Eckert, J. (1996): Cestodes: Echinococcus. Gastroenter. Clin. North Am., 25: 655–689 http://dx.doi.org/10.1016/S0889-8553(05)70268-510.1016/S0889-8553(05)70268-5Search in Google Scholar

[4] Borošková, Z., Dvorožňáková, E., Ševčíková, Z. (2003): Cellular immune reactions of mice with alveolar echinococcosis after albendazole therapy. Helminthologia, 40: 187–194 Search in Google Scholar

[5] Brajtburg, J., Bolard, J. (1996): Carrier effects on biological activity of amphotericin B. Clin. Microb. Rev., 9: 512–531 Search in Google Scholar

[6] Brajtburg, J., Powderly, W. G., Kobayashi, G. S., Medoff, G. (1990): Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother., 34: 183–188 Search in Google Scholar

[7] Bresson-Hadni, S., Liance, A., Meyer, J. P., Houin, R., Bresson, J. L., Vuitton, D. A. (1990): Cellular immunity in experimental Echinococcus multilocularis infection. II. Sequental and comparative phenotypic study of the periparasitic mononuclear cells in resistant and sensitive mice. Clin. Exp. Immunol., 82: 378–383 http://dx.doi.org/10.1111/j.1365-2249.1990.tb05457.x10.1111/j.1365-2249.1990.tb05457.xSearch in Google Scholar

[8] Capece, B. P., Navarro, M., Arcalis, T., Castells, G., Toribio, L., Perez, F., Carretero, A., Ruberte, J., Arboix, M., Cristofol, C. (2003): Albendazole sulphoxide enantiomers in pregnant rats’ embryo concentrations and developmental toxicity. Vet. J., 165: 266–275 http://dx.doi.org/10.1016/S1090-0233(02)00158-210.1016/S1090-0233(02)00158-2Search in Google Scholar

[9] Christiansen, K. J., Bernard, E. M., Gold, J. W. M., Armstrong, D. (1985): Distribution and activity of amphotericin B in humans. J. Infect. Dis., 152: 1037–1043 Search in Google Scholar

[10] Clements, J. S. Jr., Peacock, J. E. Jr. (1990): Amphotericin B revisited: reassessment of toxicity. Amer. J. Med., 88: 22–27 Search in Google Scholar

[11] Clemons, K. V., Sobel, R. A., Williams, P. L., Stevens, D. A. (2001): Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits. Antimicrob. Agents Chemother., 45: 612–615 http://dx.doi.org/10.1128/AAC.45.2.612-615.200110.1128/AAC.45.2.612-615.20019033711158765Search in Google Scholar

[12] Dvorožňáková, E., Hrčková, G., Borošková, Z., Velebný, S., Dubinský, P. (2004): Effect of treatment with free and liposomized albendazole on selected immunological parameters and cyst growth in mice infected with Echinococcus multilocularis. Parasitol. Int., 53: 315–325 http://dx.doi.org/10.1016/j.parint.2004.05.00110.1016/j.parint.2004.05.00115464441Search in Google Scholar

[13] Ehrenfreund-Kleinman, T., Domb, A. J., Jaffe, C. L., Nasereddin, A., Leshem, B., Golenser, J. (2005): The effect of amphotericin b derivatives on Leishmania and immune functions. J. Parasitol., 91: 158–163 http://dx.doi.org/10.1645/GE-337910.1645/GE-337915856892Search in Google Scholar

[14] Ellis, D. (2002): Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother., 49: 7–10 http://dx.doi.org/10.1093/jac/49.1.710.1093/jac/49.1.711751759Search in Google Scholar

[15] Emery, I., Liance, M., Deriaud, E., Vuitton, D. A., Houin, E., Leclerc, C. (1996): Characterization of T-cell immune responses of Echinococcus multilocularis-infected. Parasite. Immunol., 18: 463–472 Search in Google Scholar

[16] Geginat, G., Kretschmar, M., Walter, S., Junker, D., Hof, H., Nichterlein, T. (1999): Suppression of acquired immunity against Listeria monocytogenes by amphotericin B-mediated inhibition of CD8 T cell function. J. Infect. Dis., 180: 1186–1194 http://dx.doi.org/10.1086/31500710.1086/31500710479147Search in Google Scholar

[17] Gilbert, B. E., Wyde, P. R., Willson, S. Z. (1992): Aerosolized liposomal amphotericin B liposomes for treatment of pulmonary and systematic Cryptococcus neoformans infections in mice. Antimicrob. Agents Chemother., 36: 1466–1471 Search in Google Scholar

[18] Gottstein, B., Haag, K., Walker, M., Matsumoto, J., Mejri, N., Hemphill, A. (2006): Molecular survival strategies of Echinococcus multilocularis in the murine host. Parasitol. Int., 55: S45–S49 http://dx.doi.org/10.1016/j.parint.2005.11.00610.1016/j.parint.2005.11.00616352460Search in Google Scholar

[19] Hann, I. M., Prentice, H. G. (2001): Lipid-based amphotericin B: a review of the last 10 years of use. Int. J. Antimicrob. Agents, 17: 161–169 http://dx.doi.org/10.1016/S0924-8579(00)00341-110.1016/S0924-8579(00)00341-1Search in Google Scholar

[20] Heath, D. D. (1995): Immunology of Echinococcus infection. In Thompson, R. C. A., Lymbery, A. J. (Eds): Echinococcus and hydatid disease. CAB INTERNATIONAL, Wallingford, UK: 183–199 Search in Google Scholar

[21] Hiemenz, J. W., Walsh, T. J. (1996): Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis., 22: S133–S144 10.1093/clinids/22.Supplement_2.S133Search in Google Scholar

[22] Hrčková, G., Velebný, S. (1997): Effect of praziquantel and liposome-incorporated praziquantel on peritoneal macrophage activation in mice infected with Mesocestoides corti tetrathyridia (Cestoda). Parasitology, 114: 475–482 http://dx.doi.org/10.1017/S003118209600869410.1017/S0031182096008694Search in Google Scholar

[23] Inselmann, G., Volkmann A., Heidemann, H. T. (2000): Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and hepatic cztochrome P.450 in rats. Antimicrob. Agents Chemother., 44:131–133 http://dx.doi.org/10.1128/AAC.44.1.131-133.200010.1128/AAC.44.1.131-133.2000Search in Google Scholar

[24] Janknegt, R., DeMarie, S., Bakker-Woudenberg, I. A., Crommelin D. J. (1992): Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet., 23: 279–291 Search in Google Scholar

[25] Joly, V., Farinotti, R., Saint-Julien, L., Chéron, M., Carbon, C., Zeni, P. (1994): In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with intralipid. Antimicrob. Agents Chemother., 38: 177–183 Search in Google Scholar

[26] Karyotakis, N. C., Anaissie, E. J. (1994): Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob. Agents Chemother., 38: 2660–2662 10.1128/AAC.38.11.2660Search in Google Scholar

[27] Kilwinski, J., Jenne, L., Jellen-Ritter, A., Radloff, P., Flick, W., Kern, P. (1999): T lymphocyte cytokine profile at a single cell level in alveolar echinococcosis. Cytokine, 11: 373–381 http://dx.doi.org/10.1006/cyto.1998.043210.1006/cyto.1998.0432Search in Google Scholar

[28] Kizaki, T., Kobayashi, S., Ogasawara, K., Day, N. K., Good, R. A., Onoe, K. (1991): Immune suppression induced by protoscoleces of E. multilocularis in mice. Evidence for the presence of CD8dull suppressor cells in spleens of mice intraperitoneally infected with E. multilocularis. J. Immunol., 147: 1659–1666 10.4049/jimmunol.147.5.1659Search in Google Scholar

[29] Manfras, B. J., Reuter, S., Wendland, T., Boehm, B. O., Kern, P. (2004): Impeded Th1 CD4 memory T cell generation in chronic-persisting liver infection with Echinococcus multilocularis. Int. Immunol., 16: 43–50 http://dx.doi.org/10.1093/intimm/dxh00510.1093/intimm/dxh005Search in Google Scholar

[30] Murray, H. W. (2005): Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J. Immunol., 174: 4916–4923 Search in Google Scholar

[31] Pagé, M., Bajaouni, N., Ciqo-Mars, B., Lemieux, P. (1988): Optimization the tetrazolium based colorimetric assay for the measurement of cell number and cytotoxicity. Int. J. Immunopharmacol., 10: 785–793 http://dx.doi.org/10.1016/0192-0561(88)90001-X10.1016/0192-0561(88)90001-XSearch in Google Scholar

[32] Pérez-Serrano, J., Denegri, G., Casado, N., Rodríguez-Caabeiro, F. (1997): In vivo effect of oral albendazole and albendazole sulphoxide on development of secondary Echinococcosis in mice. Int. J. Parasitol., 27: 1341–1345 http://dx.doi.org/10.1016/S0020-7519(97)00105-710.1016/S0020-7519(97)00105-7Search in Google Scholar

[33] Persat, F., Bouhours, J. F., Mojon, M., Petavy, A. F. (1990): Analysis of the monohexosylceramide fraction of Echinococcus multilocularis metacestodes. Mol. Biochem. Parasitol., 41: 1–6 http://dx.doi.org/10.1016/0166-6851(90)90090-910.1016/0166-6851(90)90090-9Search in Google Scholar

[34] Rama-Iniguez, S., Dea-Ayuela, M. A., Sanchez-Brunete J. A., Torrado, J. J., Alunda, J. M., Bolas-Fernandez, F. (2006): Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation. Antimicrob. Agents Chemother., 50: 1195–1201 http://dx.doi.org/10.1128/AAC.50.4.1195-1201.200610.1128/AAC.50.4.1195-1201.2006Search in Google Scholar

[35] Resch, K. (1999): Cytokines. In Nijkamp F. P., Parnham, M. J. (Eds): Principles of Immunopharmacology. Birghäuser Verlag, Basel, Boston, Berlin: 53–81 Search in Google Scholar

[36] Reuben, J. M, Tanner, C. E. (1983): Protection against experimental echinococcosis by non-specifically stimulated peritoneal cells. Parasite Immunol., 5: 61–66 Search in Google Scholar

[37] Reuter, S., Jensen, B., Buttenschoen, K., Kratzer, W., Kern, P. (2000): Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J. Antimicrob. Chemother., 46: 451–456 http://dx.doi.org/10.1093/jac/46.3.45110.1093/jac/46.3.451Search in Google Scholar

[38] Reuter, S., Merkle, M., Brehm, K., Kern, P., Manfras, B. (2003a): Effect of amphotericin B on larval growth of Echinococcus multilocularis. Antimicrob. Agents Chemother., 47: 620–625 http://dx.doi.org/10.1128/AAC.47.2.620-625.200310.1128/AAC.47.2.620-625.2003Search in Google Scholar

[39] Reuter, S., Buck, A., Grebe, O., Nussle-Kugele, K., Kern, P., Manfras, B. J. (2003b): Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrob. Agents Chemother., 47: 3586–3591 http://dx.doi.org/10.1128/AAC.47.11.3586-3591.200310.1128/AAC.47.11.3586-3591.2003Search in Google Scholar

[40] Rigano, R., Profumo, E., Buttari, B., Teggi, A., Siracusano, A. (1999): Cytokine gene expression in peripheral blood mononuclear cells (PBMC) from patients with pharmacologically treated cystic echinococcosis. Clin. Exp. Immunol., 118: 95–101 http://dx.doi.org/10.1046/j.1365-2249.1999.01021.x10.1046/j.1365-2249.1999.01021.xSearch in Google Scholar

[41] Sau, K., Mambula, S. S., Latz, E., Henneke, P., Golenbock, D. T., Levitz, S. M. (2003): The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor-and CD14-dependent mechanism. J. Biol. Chem., 278: 37561–37568 http://dx.doi.org/10.1074/jbc.M30613720010.1074/jbc.M306137200Search in Google Scholar

[42] Schantz, P. M. (2002): Progress and challenges in biology, treatment and control of echinococcosis. Abstracts ICOPA X, Vancouver, Canada: 243 Search in Google Scholar

[43] Schindler, J. J., Warren, R. P., Allen, S. D., Jackson, M. K. (1993): Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and compromised mice. Antimicrob. Agents Chemother, 37: 2716–2721 10.1128/AAC.37.12.2716Search in Google Scholar

[44] Simitsopoulou, M., Roilides, E., Dotis, J., Dalakiouridou, M., Dudkova, A. F., Andreadou, E., Walsh, T. J. (2005): Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob. Agents Chemother., 49: 1397–1403 http://dx.doi.org/10.1128/AAC.49.4.1397-1403.200510.1128/AAC.49.4.1397-1403.2005Search in Google Scholar

[45] Stein, S. H., Little, J. R., Little, K. D. (1987): Parallel inheritance of tissue catalase activity and immunostimulatory action of amphotericin B in inbred mouse strains. Cell. Immunol., 105: 99–109 http://dx.doi.org/10.1016/0008-8749(87)90059-110.1016/0008-8749(87)90059-1Search in Google Scholar

[46] Sturm, D., Menzel, J., Gottstein, B., Kern, P. (1995): Interleukin-5 is the predominant cytokine produced by peripheral blood mononuclear cells in alveolar echinococcosis. Infect. Immun., 63: 1688–1697 Search in Google Scholar

[47] Šoltýs, J., Quinn, M. T. (1999): Modulation of endotoxin-and enterotoxin-induced cytokine release by in vivo treatment with β-(1,6)-branched β-(1,3)-glucan. Infect. Immun., 67: 244–252 Search in Google Scholar

[48] Šoltýs, J., Turčeková, L.’, Rycke, de P. H. (1999): The effect Echinococcus hydatid cyst fluid and protoscoleces on mouse peritoneal macrophages and spleen lymphocytes. Helminthologia, 36: 25–30 Search in Google Scholar

[49] Thompson, R. C. A. (1995): Biology and systematics of Echinococcus. In Thompson, R. C. A., Lymbery, A. J. (Eds): Echinococcus and hydatid disease. CAB INTERNATIONAL, Wallingford, UK: 1–50 Search in Google Scholar

[50] Vuitton, D. A. (2003): The ambiguous role of immunity in Echinococcosis: protection of the host or of the parasite? Acta. Trop., 85: 119–132 http://dx.doi.org/10.1016/S0001-706X(02)00230-910.1016/S0001-706X(02)00230-9Search in Google Scholar

[51] Vuitton, D. A., Zhang, S. L., Yang, Y., Godot, V., Beurton, I., Mantion, G., Bresson-Hadni, S. (2006): Survival strategy of Echinococcus multilocularis in the human host. Parasitol. Int., 55: S51–S55 http://dx.doi.org/10.1016/j.parint.2005.11.00710.1016/j.parint.2005.11.00716360335Search in Google Scholar

[52] Vuitton, D. A. (1999): New trends in the treatment of echinococcosis. Helminthologia, 36: 167–170 Search in Google Scholar

[53] Wolf, J. E., Massof, S. E. (1990): In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect. Immun., 58:1296–1300 Search in Google Scholar

[54] Yardley, V., Croft, S. L. (1999): In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am. J. Trop. Med. Hyg., 61: 193–197 Search in Google Scholar

[55] Zhang, Z., Lipman, J. M., Diener, R. M., Thomas, P. (2006): Comparative immunotoxicity evaluation of amphotericin B and ABELCET, an amphotericin B lipid complex (ABLC). Int. J. Toxicol., 25: 487–492 http://dx.doi.org/10.1080/1091581060096124210.1080/1091581060096124217132607Search in Google Scholar